Background The outcome of diffuse large B-cell lymphoma has been substantially improved
by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens …

Purpose Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using
a time-to-event approach with relapse, re-treatment, and death commonly used as the …

Background Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin,
vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients …

Purpose: Our objective was to identify the genetic changes involved in primary central
nervous system lymphoma (PCNSL) oncogenesis and evaluate their clinical relevance …

Allogeneic hematopoietic cell transplantation (allo-HCT) is indicated for patients with
relapsed or refractory Hodgkin lymphoma (HL). Although long-term disease control can be …

Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall
survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 …

Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma subtype and is
clinically aggressive. To identify genetic susceptibility loci for DLBCL, we conducted a meta …

Introduction Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)
require further treatment options, especially in cases that cannot tolerate stem cell transplant …

Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene
ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for …

Background Treatment of relapsed/refractory (R/R) primary CNS lymphoma (PCNSL) is
poorly defined, because randomized trials and large studies are lacking. The aim of this …